Theravance, Inc. Reports 2013 Financial Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, CA--(Marketwired - Feb 6, 2014) - Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the fourth quarter and full year ended December 31, 2013. Revenue for the fourth quarter and full year of 2013 was $1.6 million and $4.8 million, respectively. Net loss for the fourth quarter and full year of 2013 was $49.9 million and $170.7 million, respectively. Net loss per basic and diluted share was $0.46 and $1.67 for the fourth quarter and full year of 2013, respectively. Cash and cash equivalents, short-term investments and marketable securities totaled $520.5 million as of December 31, 2013.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC